AdvisorShares Psychedelics ETF (PSIL)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
26.80 - Open
26.56 - Bid 24.73 x 30000
- Ask 27.89 x 30000
- Day's Range
26.29 - 27.02 - 52 Week Range
15.64 - 27.02 - Volume
23,173 - Avg. Volume
42,677 - Net Assets 48.53M
- NAV 26.39
- PE Ratio (TTM) --
- Yield 7.30%
- YTD Daily Total Return 56.09%
- Beta (5Y Monthly) 0.56
- Expense Ratio (net) 1.00%
Performance Overview
View MoreTrailing returns as of 8/25/2026. Category is Miscellaneous Sector.
Holdings
View MoreTop 10 Holdings (70.03% of Total Assets)
Sector Weightings
Recent News
View MoreResearch Reports
View More-
Rating increased to a HOLD
Schrodinger Inc/United States has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target -
Johnson & Johnson Earnings: A Steady 2025 and Improving 2026 Warrant a FVE Increase
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
RatingPrice Target -
Pfizer Earnings: In-Line Quarter Despite Covid Product Weakness as Metsera Drama Intensifies
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
RatingPrice Target -
Pfizer: Metsera Acquisition Puts Firm Back in Contention in Potential $200 Billion GLP-1 Market
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
RatingPrice Target
